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Abstract
Background: Since the incidence of the histological subtypes of lung cancer in industrialised countries has changed
dramatically over the last two decades, we reviewed trends in the incidence and prognosis in North America,
Australia, New Zealand and Europe, according to period of diagnosis and birth cohort and summarized explanations
for changes in mortality. Methods: Review of the literature based on a computerised search (Medline database
1966–2000). Results: Although the incidence of lung cancer has been decreasing since the 1970s:1980s among men in
North America, Australia, New Zealand and north-western Europe, the age-adjusted rate continues to increase
among women in these countries, and among both men and women in southern and eastern Europe. These trends
followed changes in smoking behaviour. The proportion of adenocarcinoma has been increasing over time; the most
likely explanation is the shift to low-tar filter cigarettes during the 1960s and 1970s. Despite improvement in both the
diagnosis and treatment, the overall prognosis for patients with non-small-cell lung cancer hardly improved over time.
In contrast, the introduction and improvement of chemotherapy since the 1970s gave rise to an improvement in —
only short-term (B2 years) — survival for patients with small-cell lung cancer. Conclusions: The epidemic of lung
cancer is not over yet, especially in southern and eastern Europe. Except for short-term survival of small cell tumours,
the prognosis for patients with lung cancer has not improved significantly. © 2001 Elsevier Science Ireland Ltd. All
rights reserved.
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1. Introduction
At the beginning of this century lung cancer
was a very rare disease, but rates in North Amer-
ica, Australia, New Zealand and Europe have
increased so dramatically that lung cancer can be
considered a major epidemic of the 20th century.
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Currently lung cancer is the first or second most
frequent tumour type among men in industrialised
countries and ranks second or third for women
[1–5].
Trends in mortality are influenced by trends in
incidence and survival. Since the incidence of the
histological subtypes of lung cancer in industri-
alised countries has changed dramatically over the
last two decades, we now review time and
birth cohort trends in the incidence and prognosis
of lung cancer in North America, Australia, New
Zealand and Europe according to geography and
histological subtype, and summarise explanations
for the changes in mortality. Trends in
incidence are described in the first part of this
review, while the second part focuses on trends in
prognosis, which so far have received little atten-
tion. We focused on industrialised countries, be-
cause the epidemic of smoking and the sub-
sequent temporarily very high incidence of
lung cancer in these countries are illustrative for
other parts of the world where smoking is on the
rise.
2. Methodological considerations
This review was based on a computerised
search (Medline database 1966–2000). Included
were English-written, peer-reviewed articles on
trends in incidence, mortality, risk factors,
prognostic factors and survival for the histological
subtypes of lung cancer. We also used volumes IV
to VII of ‘Cancer Incidence in Five Continents’,
in which incidence of cancer in different
geographical locations and distinct ethnic
sub-populations between 1973 and 1992 are de-
scribed.
2.1. Classification
Lung cancer is commonly classified as small-cell
carcinoma and a heterogeneous group of non-
small-cell carcinomas, which includes squamous
cell carcinoma, adenocarcinoma, large-cell car-
cinoma, and some rare subtypes, such as
adenosquamous cell carcinoma, mucoepidermoid
carcinoma and adenoid cystic carcinoma. The first
histological classification of lung tumours by the
World Health Organization (WHO) was pub-
lished in 1967 and revised in 1981 [6]. The major
difference between these two classifications was
that a solid carcinoma with mucus formation was
classified as ‘large-cell carcinoma’ in 1967, and as
‘adenocarcinoma’ in 1981. In some papers undif-
ferentiated carcinomas were included in the group
of ‘large-cell undifferentiated carcinomas’, in oth-
ers they were not. Large-cell undifferentiated car-
cinoma has frequently been called a ‘wastebasket’
or nonentity, because the carcinomas are so
poorly differentiated that squamous or glandular
differentiation is no longer evident at the light
microscopic level. Thus, the incidence of this his-
tological subtype varies with the criteria used to
classify the other forms of non-small-cell lung
cancer. Primary adenocarcinoma of the lung may
be difficult to distinguish from pulmonary metas-
tases of adenocarcinoma of the breast, prostate,
colon, rectum or stomach. However, in most pop-
ulation-based or hospital-based registries the diag-
nosis is corrected when the primary tumour is
found. Although bronchioloalveolar carcinoma is
a distinct pathological entity, it is similar to ade-
nocarcinoma as far as gender, stage, race and age
distribution are concerned, but prognosis of bron-
chioloalveolar is probably better [7–9].
2.2. Quality of the data
There are differences in completeness of data
between the various countries. This depends not
only on the completeness of cancer registries but
also on the degree of ascertainment (access to
specialised care and the availability and quality of
death certificates). Access to specialised care de-
pends on the number of chest physicians and:or
internists per one million inhabitants, the distance
to hospitals and the extent of health insurance
coverage. The completeness of cancer registries
also depends on the number of sources of data,
such as the pathological laboratory, hospital
record offices and radiotherapy institutes. An-
other indicator of the completeness of the data is
the mortality:incidence ratio, which should be
almost equal to one in the case of this lethal
disease [2].
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2.3. Stage migration
When reporting on trends in stage distribution
one should take ‘stage migration’ into account:
through improved diagnostic techniques lymph
node involvement or distant metastases can be
found more easily, thus some tumours that were
identified as localised in the past will be consid-
ered as metastasised today [10]. Stage migration
will result in a better prognosis for each stage
group.
3. Trends in incidence
3.1. Geographical 6ariations
Worldwide male lung cancer incidence rates
between 1988 and 1992 were highest (\50 per
100 000 person-years) in the USA, Canada, New
Zealand (Maori) and most European countries,
moderate (35–50 per 100 000) in China, Ireland,
Malta, Spain, Australia and New Zealand (non-
Maori), and low (B35 per 100 000) in Utah
(USA), Latin America, most Asian countries, Ice-
land, Norway and Sweden [2]. For women lung
cancer incidence rates were exceptionally high (\
50 per 100 000) in New Zealand (Maori), high
(20–50 per 100 000) in the USA, Canada, Den-
mark, Iceland and the UK, moderate (10–20 per
100 000) in Australia, New Zealand (non-Maori),
Utah (USA), Austria, Germany, Ireland, The
Netherlands, Norway, Poland, Sweden, Switzer-
land and Asia, and low (B10 per 100 000) in
Latin America, other European countries, India
and Africa [2].
Incidence rates for lung cancer in industrialised
countries have changed markedly over the past
two decades. Fig. 1 shows the trends in age-stan-
dardised incidence rates. In North America, Aus-
tralia, New Zealand and most countries of
northwestern Europe the age-standardised rate
for men increased markedly up to the 1970s or
1980s and then started to decline first among
middle-aged men and later in the older age groups
[3,11–22]. In southern and eastern Europe the
peak in incidence was not reached at the begin-
ning of the 1990s [2,20,23–25]. For women lung
cancer incidence (being much lower than that for
men) started to increase later and is still on the
rise, except in southern Ireland and Switzerland
(Geneva). In the USA, The Netherlands, Italy and
Switzerland the highest rates were found for men
born between 1910 and 1930 and women born
after 1930 [16,17,19,20,26].
3.2. Variations between histological types
The trends in lung cancer incidence were not
the same for every histological type. Among men
in the USA and Western Europe the age-stan-
dardised incidence rate for squamous cell car-
cinoma rose to 25–60 per 100 000 person-years in
the early 1980s and then declined to 20–40 in the
1990s. The same trend was found for small-cell
carcinoma, the peak (12–18 per 100 000 person-
years) also being reached at the beginning of the
1980s. The rates for adenocarcinoma rose from
5–15 per 100 000 person-years in the 1970s to
10–35 in the 1990s [14,16–19,21,27–30]; in the
USA (black men) and the southeastern part of
The Netherlands the peak was reached at the end
of the 1980s; for white American men a plateau
was reached in the early 1990s [17,18]. In other
countries the peak in the incidence of adenocar-
cinoma had not been reached at the beginning of
the 1990s.
Among European women the incidence rate for
every histological type increased from 1–2 per
100 000 in the 1970s to 2–5 in the 1990s [14,16–
19,21,27–30]. However, for American women the
rise in the incidence of adenocarcinoma from 2–7
per 100 000 to 13–15 was marked [16,18,21]. In
Australia and Europe squamous cell carcinoma is
still the most common type of cancer among men,
whereas in North America adenocarcinoma is
now the leading lung cancer cell type among both
men and women (Fig. 2). Adenocarcinoma is
relatively more common in women (representing
about one third of all lung carcinomas) than in
men (15–25% of all lung carcinomas).
There was also a birth cohort trend apparent
for the different histological subtypes of lung
cancer: squamous cell carcinoma declined among
men born after 1910–1925, whereas adenocar-
cinoma only declined among men born after
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1930–1935, or even later [16,19–21]. Among
women in Connecticut the incidence rates for
squamous cell carcinoma and adenocarcinoma
have decreased since birth cohort 1930–1939 [21],
however, in Italy and Switzerland the rates for
adenocarcinoma among women increased at least
up to the 1950–1959 cohort [19,20]. Among Swiss
women the rate for squamous cell carcinoma
started to decrease with birth cohort 1940–1949
[19].
3.3. Discussion of trends in incidence
A lot of studies published since 1948 have
indicated that smoking tobacco is the main cause
of lung cancer with latency time between the start
of smoking and lung cancer of 15 to 50 years
[31–39]. Also the number of pack-years and the
age at initiation of smoking are closely related to
lung cancer risk [40,41]. A molecular link between
a defined cigarette smoke carcinogen and human
Fig. 1. Trends in age-standardized incidence rates (WSR) per 100 000 person-years. Source: Cancer Incidence in Five Continents,
Vols. IV, V, VI, VII.
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Fig. 2. Percentage distribution of microscopically verified cases
by histological subtype (1988–1992). Source: Cancer Incidence
in Five Continents, Vols. IV, V, VI, VII.
1984 revealed that lung cancer in cigar and pipe
smokers was more likely to be a central
(squamous cell or small-cell carcinoma) than a
peripheral lesion (adenocarcinoma); the authors
speculated that cigar and pipe smoke are not
inhaled as deeply as cigarette smoke [52]. Other
causes of lung cancer have been identified, such as
air pollution [53], occupational exposure to as-
bestos or radon (however, only a small proportion
of the population was exposed) [54–56], vitamin
A deficiency [57–61], indoor radon [62], possibly
bird keeping [63–68], and previous chronic lung
diseases [69–72], but the effects of smoking are so
predominant that trends in other exposures seem
unlikely to be largely responsible for the changes
in incidence.
The trends in lung cancer incidence for both
sexes followed the temporal and geographical
variations in smoking behaviour after 15–25
years. The percentage of smokers among men
was much higher than among women but has
dropped since the 1950s:1960s, first among
younger men [49,73–76]. While the prevalence of
smoking has decreased since the 1950s, the per-
centage low-tar filter cigarette smokers
among smokers has increased markedly [74,77–
79]. However, those who continued smoking were
the heavily addicted ones [80]. In southwestern
Europe the percentage of smokers did not start to
decrease until the 1980s and in many eastern
European countries the prevalence of smoking
increased until the 1990s [76]. The very low inci-
dence of lung cancer in Norway and Sweden can
be explained by the strong anti-smoking cam-
paigns in these countries [48,76]. The low inci-
dence in Utah is probably due to the high
proportion (about 70%) of Mormons, who are
discouraged from smoking. The relatively high
incidence among women in New Zealand
(Maori) can be explained by the high percentage
of smokers.
The decrease in incidence rates for squamous
cell carcinoma and small cell carcinoma was prob-
ably due to a decrease in the percentage of smok-
ers since the 1950s and to a change to low-tar
filter cigarettes. This was not the same for men
and women, nor for all age groups. The percent-
lung cancer mutations was not found until 1996
[42]. The relative risks of smoking are two to four
times higher for squamous cell carcinoma and
small-cell carcinoma (RR between 10 and 50)
than for adenocarcinoma (RR between 2 and 15)
[36,40,43–48]. The decline in risk after quitting
smoking was also more consistent for squamous
cell, small-cell and large-cell undifferentiated car-
cinoma than for adenocarcinoma [49]. However,
the lower risk for adenocarcinoma could also be
spurious, because the risk of adenocarcinoma in
non-smokers (reference group) is also higher
[36,43,48,49]. The association between smoking
and lung cancer cell types seems to be related to
tumour location: adenocarcinoma is known to
occur primarily in the peripheral lung zones,
whereas squamous cell carcinoma and small-cell
carcinoma occur mainly in central or hilar loca-
tions [36,40,50,51]. The association between
smoking and lung cancer cell type is probably
related to the inhalation pattern. A case-control
study conducted in the USA between 1977 and
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age of female smokers was much lower than the
percentage of male smokers and started to de-
crease only at the end of the 1970s. This has
resulted in an increase in incidence up to the
1990s. Among men both a period effect (decrease
in the percentage of smokers since the 1950s and
a change to more low-tar filter cigarettes) and a
birth cohort effect (mainly the elderly — referring
to the earlier birth cohorts — continued smoking
non-filter, high-tar cigarettes) occurred.
The increase in adenocarcinoma is more
difficult to explain. The extent to which changes
in diagnostic techniques or classification were re-
sponsible for the increase in adenocarcinoma is
likely to be small [21,30,81,82]: solid carcinoma
with mucus production, only being classified as
‘adenocarcinoma’ after 1981 [6], is a very small
group and is, therefore, probably not responsible
for the major part of the increase. Furthermore,
the inter-observer reproducibility for adenocar-
cinoma was good [83–85]. There are several hy-
potheses about changes in smoking behaviour,
which could explain the increase in adenocar-
cinoma, which occurs primarily in the peripheral
lung zones. First, the introduction of filter
cigarettes since the mid-1950s may have led to an
increase in the incidence of adenocarcinoma, be-
cause filters are less effective in eliminating
smaller particles and filter use could also result in
taking larger puffs and retaining smoke longer to
compensate for the lower nicotine yield
[21,36,49,78,86]. Since a study within the SEER
database revealed that the increase in adenocar-
cinoma only occurred in smokers [21], the in-
creased use of filter cigarettes seems to be a
plausible explanation for the rise. Moreover, a
multicentre hospital-based case-control study in
the USA revealed that the risk of squamous cell
carcinoma for smokers of filter cigarettes was
lower than for smokers of non-filter cigarettes,
but the risk of adenocarcinoma was not reduced
[78]. A second, complementary hypothesis sug-
gests that smoking low-tar filter cigarettes may
increase the risk for adenocarcinoma because
these cigarettes have a higher nitrate content. The
increased yields of N-nitrosamines, especially
NNK, induced adenocarcinoma of the lung in
laboratory animals [87]. The higher proportion of
Americans with adenocarcinoma can also be ex-
plained by the higher proportion of smokers who
smoke low-tar filter cigarettes in the USA (almost
100% in 1992) compared to European countries
(about 70%) [48,77]. The higher proportion of
women with adenocarcinoma can also be ex-
plained by past smoking behaviour. Prior to the
1950s cigarettes were predominantly unfiltered,
high-tar products smoked largely by men. In the
1950s, when women were just beginning to smoke,
filter cigarettes were introduced and thus repre-
sented less of a change for women than for men.
This has resulted in a higher baseline proportion
of women with adenocarcinoma. Most of the
temporal and geographical variations in lung can-
cer rates are thus probably related to different
patterns of past smoking behaviour.
3.4. Conclusions concerning trends in incidence
Although the peak of lung cancer incidence
among men in North America, Australia, New
Zealand and northwestern Europe was reached in
the 1980s, the rate for men in southern and east-
ern Europe and for women continued to increase,
at least until the 1990s. The decrease in incidence
first occurred in younger men, thus the proportion
of elderly patients has been increasing.
The trends in incidence were closely associated
with past smoking behaviour. Despite a decrease
since the 1950s the percentage of smokers reached
a plateau of 30–50% in the mid-1980s and
teenagers have even been smoking more since
1990 [76]. Furthermore, the average number of
cigarettes smoked per day has increased, because
the smokers who continued smoking were the
heavily addicted ones. Thus, the decrease in lung
cancer incidence will probably reach a plateau in
the beginning of the next century, but for those
born after 1970 there will probably be an increase
of lung cancer incidence after 2010.
The trend toward smoking more low-tar filter
cigarettes probably caused the increase in the
incidence of adenocarcinoma. This tumour type is
already the major histological subtype in North
America and may also become the major type in
Australia, New Zealand and Europe in the near
future. It is very likely that adenocarcinoma will
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give rise to a new epidemic, although it probably
will not reach the same magnitude as that of
squamous cell carcinoma.
4. Trends in prognosis
4.1. Geographical 6ariations
Worldwide, the prognosis for patients with lung
cancer is very poor, because metastases are often
present at the time of diagnosis. Survival is associ-
ated with age and tumour stage: 1-year relative
survival rates decreased from 40% for patients
younger than 45 years old to 20% for patients of
75 and older [88,89], and was better for patients
with localised disease (40–65%) than for those
with metastasised disease (15–30%) [80,90–92].
In North America the 1- and 5-year survival
rates in the 1980s were about 30 and 12%, respec-
tively, [93–96]. Between European countries fairly
large variations in lung cancer survival rates ex-
isted between 1978 and 1989: 1-year rates varied
between 21 and 42%, and 5-year rates between 5
and 15%, being highest in Finland, France, The
Netherlands and Switzerland, and lowest in Den-
mark, England, Poland and Scotland [88–
90,97,98].
Between 1975 and 1990 the prognosis for lung
cancer patients, regardless of histological type,
improved slightly although not significantly over
time [88,89,93,95,96,98–100].
4.2. Variations between histological subtypes
Besides being dependent on age and tumour
stage, survival for lung cancer patients is closely
related to the histology of the tumour. Survival
was best for patients with non-small-cell car-
cinoma and poorest for patients with small-cell
carcinoma [90,92,93,97,101–106]. Despite recent
advances in treatment the 5-year survival rate for
patients with non-small-cell lung cancer is still less
than 15% and that for small-cell carcinoma only
5% [92,94,97,107,108].
Although non-small-cell lung cancer is often
considered to be one clinically uniform category,
several studies indicate that survival differs ac-
cording to histological subtype, being better for
squamous cell carcinoma and adenocarcinoma (1-
year survival rates of 40–50%) than for large-cell
undifferentiated carcinoma (1-year survival rates
of 25–30%) [90,92,94,97,101,103,109]. In York-
shire, England, UK, the population-based sur-
vival for each histological subtype of
non-small-cell lung cancer remained largely un-
changed between 1976 and 1983 [110]; however,
the percentage of patients with an unknown his-
tology was very high [111]. In contrast, in the
southeastern part of The Netherlands the popula-
tion-based relative 1-year survival rates for adeno-
carcinoma decreased markedly from 59% in 1975
to 45% in 1992, while that for squamous cell
carcinoma remained about 50% and that for
large-cell undifferentiated carcinoma remained
about 30% [92].
Small-cell lung cancer can be distinguished
from other forms of lung cancer. Its features are:
rapid progression, short doubling time, high
growth fraction, and sensitivity to multiple
chemotherapeutic agents and radiation therapy.
Short-term survival seems to have improved since
the introduction of chemotherapy in the 1970s
[107,108,112]. In Mersey and Yorkshire, England,
UK, the population-based 2-year survival rate
improved from 2% in the 1970s to 8% in the 1980s
and in the southeastern part of The Netherlands
the population-based relative 1-year survival rate
improved from 15% in the 1970s to 35% in the
1980s, but there was no further improvement in
the 1990s and 2-year survival did not exceed 8%
[106,113].
4.3. Discussion of trends in prognosis
Despite the improvement in survival for small-
cell lung cancer, the overall prognosis for lung
cancer remained poor and 5-year survival rates
still do not exceed 15%. Until now, the only real
chance of cure is surgery for patients with limited
disease [97,104,114,115]. About 30% of the pa-
tients with non-small-cell carcinoma have under-
gone surgical treatment since the 1980s compared
to only 5% of those with small-cell carcinomas
[103,116]. Postoperative mortality, which is higher
for the elderly, is related to the type of resection,
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the risk being highest (6%) after pneumonectomy
[117].
The proportion of patients undergoing surgery
decreased slightly between 1974 and 1986; for
smaller lesions a trend was apparent toward more
lung-sparing resections; the use of radiotherapy
has increased since the 1980s [93,118]. Selection
for surgery has probably improved as a result of
the introduction of flexible bronchoscopy, isotope
scanning and computerised tomography as well as
mediastinoscopy. These diagnostic techniques
have probably increased the detection of metas-
tases (stage migration). With the exception of
small-cell carcinoma there was almost no change
in the proportion of patients receiving chemother-
apy in the USA and the UK [93,118].
The prognosis for lung cancer varied markedly
between countries, probably due to differences in
(1) detection of disease, (2) inclusion of patients in
studies (selected or unselected cases, patients dead
around diagnosis), (3) methods of data collection
and completeness (depending on access to medical
care and the quality and availability of death
certificates), (4) methods of calculating survival
(crude, disease-specific or relative survival) and (5)
access to specialised care. Furthermore, the
availability of medical expertise and facilities is
dependent on the number of chest physicians and
internists per 100 000 inhabitants. It is also influ-
enced by geographical and socio-economic fac-
tors, including distance from specialised centres
and the extent of health insurance coverage.
4.4. Non-small-cell lung cancer
Survival of non-small-cell carcinoma is closely
associated with tumour stage and treatment. The
treatment-of-first-choice for patients with stage I
or II non-small-cell lung cancer is surgical resec-
tion [119]. Even for elderly lung cancer patients
pulmonary resection is justified, however, a care-
ful preoperative assessment ought to be per-
formed and standard resections should be
preferred [120,121]. Some patients with stage IIIa
disease will qualify for surgical resection, others
should be offered combined radiotherapy and
chemotherapy. For most patients with stage IIIb
disease, the preferred therapeutic modality is tho-
racic radiotherapy in combination with
chemotherapy [119]. For patients with stage IV
lung cancer, no curative treatment or ‘standard
therapy’ is available [119,122]. Although radio-
therapy was applied sparingly either alone or in
combination with chemotherapy for non-small-
cell lung cancer, its use has doubled in the last few
decades [100]. Adjuvant chemotherapy produces a
significant but clinically small advantage for non-
small-cell lung cancer patients and should still be
considered experimental [119,123]. Typing of
oncogenes or tumour suppressor genes may
provide a more accurate diagnosis and, therefore,
facilitate the planning of suitable therapeutic ap-
proaches, e.g. adjuvant chemotherapy shortly af-
ter undergoing surgery for patients with
cytokeratin 18 positive stage I non-small-cell lung
cancer [124–129].
Despite an excellent description of the tumour’s
size and the extent of anatomic spread, the tu-
mour node metastasis (TNM) system does not
include important prognostic factors that are
manifest in the clinical condition of the patient
[130–133]. Since the proportion of elderly patients
in most Western countries is growing, co-morbid-
ity or the coexistence of various chronic illnesses
in addition to the index disease is of growing
importance for the clinical management (espe-
cially surgical management) of lung cancer pa-
tients. Co-morbidity increases the risk of
peroperative and postoperative complications
[134–137], especially those of the cardiorespira-
tory system [117,120,121,138,139]. Co-morbidity
is also an independent prognostic factor [140–
145]. Indeed co-morbidity in elderly patients was
found to be associated with less surgery and poor
survival [100,146].
In the southeastern part of The Netherlands a
marked decrease in survival for patients with ade-
nocarcinoma was found, despite increased appli-
cation of better diagnostic techniques by more
chest physicians [92]. The decrease in survival
might partly be explained by the lift of screening
for tuberculosis since the early 1980s and is possi-
bly partly due to the higher concentration of
carcinogens in the peripheral lung zones — due
to the increased use of filter cigarettes — which
may have caused a more rapidly metastasising
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tumour. This needs to be confirmed in other
countries.
4.5. Small-cell lung cancer
Prior to 1970 irradiation and sometimes surgery
were the major modes of treatment of small-cell
lung cancer. The overall 5-year survival rate with
surgery was B1–3%, even for patients with clini-
cally resectable disease. Neither preoperative nor
postoperative radiotherapy improved the poor re-
sults of surgery [147]. Currently, small-cell lung
cancer patients with limited disease generally re-
ceive combination chemotherapy and radiother-
apy, and approximately 50% experience complete
clinical remission. Patients with extensive disease
also exhibit an initial response to chemotherapy,
but only 20–40% go into complete remission.
Although the introduction of intensive combina-
tion chemotherapy in the 1970s has resulted in an
increase in survival [110,118], death from recur-
rent disease occurs within 2 years of diagnosis in
80–98% of the cases [113,148–151]. Furthermore,
results of chemotherapy have reached a plateau
and further improvement seems impossible with
the currently available tools [106–108,152]. The
response rates and survival rates after combina-
tion chemotherapy with irradiation were moder-
ately higher than after combination chemotherapy
alone [112,153–156].
For elderly patients, whose proportion has been
increasing, the survival rate was lower [113,157–
159]. This could also be related to the presence of
co-morbidity, which may complicate treatment
and deteriorate the prognosis [135–137,160–162].
4.6. Conclusions concerning trends in prognosis
Despite earlier detection through the increased
use of flexible bronchoscopy and fine needle aspi-
ration cytology, lymphatic and hematogenous
metastases are often present at the time that lung
cancer is diagnosed, and prognosis is still very
poor. Survival of lung cancer differs markedly,
according to histological subtype. The prognosis
for non-small-cell lung cancer has remained ap-
proximately constant, while the prognosis for ade-
nocarcinoma — one of the subtypes of
non-small-cell lung tumours — may even be de-
creasing over time. In contrast, progress has been
made in the short-term survival of small-cell lung
cancer — due to the introduction of chemother-
apy since the 1970s — but it has stabilised since
the mid-1980s and 2-year survival remains very
poor. The growing proportion of elderly patients
who often present with serious co-morbidity at
diagnosis complicates treatment and indicates the
need for adapted guidelines for these patients,
who usually are not entered in clinical trials.
5. Summary and conclusions
Since the beginning of this century the inci-
dence of lung cancer has been increasing dramati-
cally in most Western countries; it is now the
most frequent or second most frequent tumour in
men and the second or third in women. The peak
of the epidemic among men was reached in the
1970s or 1980s in North America, Australia, New
Zealand and north-western Europe, first in the
younger age groups. The peak among men in
southern and Eastern Europe and for women has
not yet been reached. The trends were not the
same for every histological subtype of lung can-
cer. Among men the incidence of squamous cell
carcinoma and small-cell carcinoma started to
decrease earlier than that of adenocarcinoma.
These trends followed changes in smoking be-
haviour. Among men the proportion of smokers
has increased markedly since the beginning of this
century but has decreased since the 1950s or
1960s, except in southern and eastern Europe.
Younger men were more inclined to quit smoking
or to switch to low-tar filter cigarettes than the
elderly. Women only started smoking in the 1950s
and the percentage of female smokers did not
decrease before the 1970s.
The incidence of and proportion of patients
with adenocarcinoma have been increasing. Many
studies have made it plausible that this increase is
related to a shift from high-tar non-filter
cigarettes toward low-tar filter cigarettes during
the 1960s and 1970s, especially since the increase
in adenocarcinoma was found to occur only in
smokers.
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Despite improvement in both the diagnosis —
as a result of flexible bronchoscopy — and treat-
ment, the overall prognosis for patients with non-
small-cell lung cancer did not improve
significantly over time. Recognition of specific
patterns of mutational activation of oncogenes or
disruption of tumour suppressor gene function,
such as K-ras or cytokeratin 18, may facilitate
tailor-made treatment and improve the prognosis
for certain subgroups. In contrast, the introduc-
tion and improvement of chemotherapy since the
1970s gave rise to an improvement in — only
short-term (B2 years) — survival for patients
with small-cell lung cancer. New (combinations
of) chemotherapeutic agents intend to improve
long-term survival for patients with small-cell
lung cancer. Studies on therapy should also focus
on improvement of the treatment of adenocar-
cinoma, because more lung cancer patients will
present with this histological subtype.
In this review we have shown that the trends in
the incidence of lung cancer in industrialised
countries were closely associated with past smok-
ing behaviour by birth cohort. Furthermore, ex-
cept for the improvement in short-term survival of
small-cell lung cancer, the prognosis has not
changed significantly over the last two decades.
Since mortality is influenced by both incidence
and survival the following trends in mortality can
be expected in the near future.
First, the decrease in mortality among men in
North America, Australia, New Zealand and
northwestern Europe will reach a plateau at the
beginning of the next century because of the
steady percentage of smokers since the 1980s and
a more or less steady survival. However, the
incidence of lung cancer among those born since
1970 will probably increase after 2010, because
teenagers have been smoking more since 1990.
Among women in these regions mortality will
start decreasing soon and will also stabilise at the
beginning of the next century; the same trend is
expected for men and women in southern Europe.
In eastern Europe the percentage of smokers in-
creased until the 1990s, thus a decrease in mortal-
ity is not expected before the year 2010. In other
parts of the world, where smoking is still increas-
ing, mortality due to lung cancer will increase
dramatically in the next decades. Smoking can
only be countered by a combined strategy of
decreasing the availability of cigarettes, e.g. by
increasing the price, and developing better strate-
gies for handling nicotine addiction by offering
less harmful nicotine delivery systems.
Second, the mortality of adenocarcinoma will
probably increase worldwide, due to the increased
use of low-tar filter cigarettes. In contrast, mortal-
ity due to squamous cell carcinoma and small-cell
carcinoma will probably decrease because of a
decrease in incidence and steady or slightly in-
creasing survival rates.
In short, the epidemic of lung cancer in indus-
trialized countries is not over yet, especially in
southern and eastern Europe. Except for short-
term survival of small cell tumours, the prognosis
for patients with lung cancer has not improved
significantly.
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